AnaptysBio, Inc.
36.12-0.04 (-0.11%)
Oct 29, 4:00:02 PM EDT · NasdaqGS · ANAB · USD
Key Stats
Market Cap
1.01BP/E (TTM)
-Basic EPS (TTM)
-4.39Dividend Yield
0%Recent Filings
8-K
ANB033 Phase 1a data released
AnaptysBio hosted an investor call on October 14, 2025, unveiling Phase 1a data for ANB033, a CD122 antagonist targeting autoimmune inflammation via IL-15 and IL-2 inhibition. The trial in 80 healthy volunteers showed favorable safety with no serious adverse events, rapid pharmacokinetics supporting subcutaneous dosing, and over 50% reduction in key immune cells like NK and CD8+ T cells, returning to baseline within three months. ANB033 advances to Phase 1b in celiac disease, aiming to prevent gluten-induced mucosal damage in 60 patients, with top-line data by year-end 2026. No safety signals emerged despite cell reductions.
8-K
AnaptysBio plans business split
AnaptysBio announced plans to split into two independent public companies by year-end 2026: a lean Royalty Management Co handling Jemperli royalties from GSK—tiered up to 25% on sales exceeding $2.5 billion, with Sagard paydown eyed mid-2027 to Q2 2028—and a Biopharma Co advancing immunology assets like rosnilimab, with UC Phase 2 data due November/December 2025. This carve-out aims to sharpen investor focus on royalties' steady upside versus pipeline risks, while minimizing taxes. Separation hinges on board approval and SEC filing.
10-Q
Q2 FY2025 results
AnaptysBio posted collaboration revenue of $22.3 million in Q2 FY2025 ended June 30, 2025, up 103% y/y from $11.0 million, driven by higher royalties from GSK's Jemperli and Zejula sales, while YTD revenue doubled to $50.0 million from $18.2 million. Operating expenses dipped 6% y/y to $48.4 million, yielding a narrower operating loss of $26.2 million versus $40.3 million last year, thanks to controlled R&D outlays on rosnilimab and other pipeline assets. Yet net loss widened to $38.6 million from $46.7 million, as non-cash interest expense on royalty monetizations surged 79% y/y to $19.6 million from the Jemperli amendment. Cash and equivalents fell to $44.3 million from $123.1 million year-end, with $293.7 million total liquidity supporting operations for at least 12 months; the company repurchased $55.5 million in shares under its program. Competition in immunology therapeutics remains fierce.
8-K
AnaptysBio Q2 results boost pipeline
AnaptysBio reported Q2 2025 financials, highlighting positive Phase 2b rosnilimab data in rheumatoid arthritis with JAK-like efficacy through Week 38 and durable off-drug responses. Enrollment wrapped in the Phase 2 ulcerative colitis trial, eyeing top-line Week 12 results in Q4 2025. Cash stood at $293.7 million, funding operations through 2027, while a $75 million GSK milestone looms from Jemperli's strong sales. Net loss narrowed to $38.6 million from $46.7 million year-over-year. Pipeline advances, but trial risks persist.
8-K
Annual meeting elects directors
AnaptysBio's stockholders, at the June 17, 2025 annual meeting, elected Rita Jain, M.D., John Orwin, and J. Anthony Ware, M.D., as Class II directors for three-year terms, while ratifying KPMG LLP as auditors and approving the amended 2017 Equity Incentive Plan, which reserves 13,520,410 shares plus prior plan carryovers for employee incentives. The advisory vote favored annual say-on-pay, with strong support for executive compensation. Directors secured. This bolsters governance continuity amid biotech talent competition.
ABCL
AbCellera Biologics Inc.
5.62-0.01
ADPT
Adaptive Biotechnologies Corpor
16.80-0.10
ANNX
Annexon, Inc.
3.19-0.26
ANTX
AN2 Therapeutics, Inc.
1.30+0.01
ANVS
Annovis Bio, Inc.
2.20+0.10
CLYM
Climb Bio, Inc.
2.08+0.00
IBRX
ImmunityBio, Inc.
2.42-0.16
IMAB
I-MAB
4.63-0.01
INAB
IN8bio, Inc.
2.00-0.10
SABS
SAB Biotherapeutics, Inc.
3.04+0.02